Pranlukast

CAS NO.：103177-37-3
Empirical Formula: C27H23N5O4
Molecular Weight: 481.5
MDL number: MFCD00864631
EINECS: 808-178-9
SAFETY DATA SHEET (SDS)
Update Date: 2026-01-30 16:22:46

What is Pranlukast?

Description

Pranlukast, a novel chromone derivative, was introduced in Japan for the treatment of bronchial asthma and allergic diseases. Pranlukast is a highly potent, selective and competitive antagonist of peptidoleukotrienes with high affinity for the LTD₄ receptor. In patients with bronchial asthma, pranlukast was reported to induce significant improvement in both immediate and late asthmatic response induced by antigen. Pranlukast is also being evaluated clinically for the treatment of perennial allergic rhinitis, pediatric asthma, and cutaneous pruritus in dialysis patients. The therapeutic potential of pranlukast in managing irritable bowel syndrome has been suggested.

Chemical properties

Off-white solid

Originator

Ono (Japan)

The Uses of Pranlukast

Labeled Pranlukast, intended for use as an internal standard for the quantification of Pranlukast by GC- or LC-mass spectrometry.

The Uses of Pranlukast

A potent, selective and orally active CysLT receptor antagonist. Leukotriene antagonist. Used as an antiasthmatic

The Uses of Pranlukast

antiasthmatic;leukotriene receptor-1 antagonist

What are the applications of Application

ONO 1078 is a CysLT1 antagonist that downplays contraction of smooth airway muscle

Definition

ChEBI: N-[4-oxo-2-(2H-tetrazol-5-yl)-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide is a member of chromones.

brand name

Onon

Biological Activity

Selective cysteinyl leukotriene receptor 1 (CysLT 1 ) antagonist (IC 50 values are ~ 4-7 and 3620 nM for CysLT 1 and CysLT 2 respectively). Inhibits contraction of airway smooth muscle, microvascular leakage into airways and eosinophil infiltration. Can decrease symptoms of bronchial asthma.

References

1) Nakai?et al. (1988),?New Potent Antagonists of Leukotrienes C4 and D4. 1. Synthesis and Structure-Activity Relationships; J. Med. Chem.?31?84 2) Taniguchi?et al.?(1993),?The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects; J. Allergy Clin. Immunol.?92?507 3) Ciana?et al.?(2006),?The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor; EMBO J.?25?4615 4) Hennen?et al. (2013),?Decoding Signaling and Function of the Orphan G Protein-Coupled Receptor GPR17 with a Small-Molecule Agonist; Sci. Signal.?6?ra93

Properties of Pranlukast

Melting point:	236-238°C
Density	1.374±0.06 g/cm3(Predicted)
storage temp.	Sealed in dry,Store in freezer, under -20°C
solubility	Soluble in DMSO (up to 25 mg/ml)
form	solid
pka	4.96±0.10(Predicted)
color	White
Merck	14,7710
Stability:	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
CAS DataBase Reference	103177-37-3(CAS DataBase Reference)

Safety information for Pranlukast

Signal word	Warning
Pictogram(s)	Exclamation Mark Irritant GHS07
GHS Hazard Statements	H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H413:Hazardous to the aquatic environment, long-term hazard
Precautionary Statement Codes	P264:Wash hands thoroughly after handling. P264:Wash skin thouroughly after handling. P273:Avoid release to the environment. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of soap and water. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. P332+P313:IF SKIN irritation occurs: Get medical advice/attention. P337+P313:IF eye irritation persists: Get medical advice/attention.